GB201904709D0 - Chemically modified oligonucleotides - Google Patents

Chemically modified oligonucleotides

Info

Publication number
GB201904709D0
GB201904709D0 GBGB1904709.1A GB201904709A GB201904709D0 GB 201904709 D0 GB201904709 D0 GB 201904709D0 GB 201904709 A GB201904709 A GB 201904709A GB 201904709 D0 GB201904709 D0 GB 201904709D0
Authority
GB
United Kingdom
Prior art keywords
chemically modified
modified oligonucleotides
oligonucleotides
chemically
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1904709.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProQR Therapeutics II BV
Original Assignee
ProQR Therapeutics II BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProQR Therapeutics II BV filed Critical ProQR Therapeutics II BV
Priority to GBGB1904709.1A priority Critical patent/GB201904709D0/en
Publication of GB201904709D0 publication Critical patent/GB201904709D0/en
Priority to CA3132180A priority patent/CA3132180A1/en
Priority to EP20719950.6A priority patent/EP3947679A1/en
Priority to US17/442,918 priority patent/US20220340900A1/en
Priority to PCT/EP2020/059369 priority patent/WO2020201406A1/en
Priority to CN202080026112.8A priority patent/CN113748206A/zh
Priority to AU2020250895A priority patent/AU2020250895B2/en
Priority to JP2021558932A priority patent/JP7698881B2/ja
Priority to IL286395A priority patent/IL286395A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GBGB1904709.1A 2019-04-03 2019-04-03 Chemically modified oligonucleotides Ceased GB201904709D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1904709.1A GB201904709D0 (en) 2019-04-03 2019-04-03 Chemically modified oligonucleotides
CA3132180A CA3132180A1 (en) 2019-04-03 2020-04-02 Chemically modified oligonucleotides for rna editing
EP20719950.6A EP3947679A1 (en) 2019-04-03 2020-04-02 Chemically modified oligonucleotides for rna editing
US17/442,918 US20220340900A1 (en) 2019-04-03 2020-04-02 Chemically modified oligonucleotides for rna editing
PCT/EP2020/059369 WO2020201406A1 (en) 2019-04-03 2020-04-02 Chemically modified oligonucleotides for rna editing
CN202080026112.8A CN113748206A (zh) 2019-04-03 2020-04-02 用于rna编辑的化学修饰寡核苷酸
AU2020250895A AU2020250895B2 (en) 2019-04-03 2020-04-02 Chemically modified oligonucleotides for RNA editing
JP2021558932A JP7698881B2 (ja) 2019-04-03 2020-04-02 Rna編集のための化学修飾したオリゴヌクレオチド
IL286395A IL286395A (en) 2019-04-03 2021-09-14 Chemically modified oligonucleotides for RNA editing

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1904709.1A GB201904709D0 (en) 2019-04-03 2019-04-03 Chemically modified oligonucleotides

Publications (1)

Publication Number Publication Date
GB201904709D0 true GB201904709D0 (en) 2019-05-15

Family

ID=66442894

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1904709.1A Ceased GB201904709D0 (en) 2019-04-03 2019-04-03 Chemically modified oligonucleotides

Country Status (9)

Country Link
US (1) US20220340900A1 (cg-RX-API-DMAC10.html)
EP (1) EP3947679A1 (cg-RX-API-DMAC10.html)
JP (1) JP7698881B2 (cg-RX-API-DMAC10.html)
CN (1) CN113748206A (cg-RX-API-DMAC10.html)
AU (1) AU2020250895B2 (cg-RX-API-DMAC10.html)
CA (1) CA3132180A1 (cg-RX-API-DMAC10.html)
GB (1) GB201904709D0 (cg-RX-API-DMAC10.html)
IL (1) IL286395A (cg-RX-API-DMAC10.html)
WO (1) WO2020201406A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115697420A (zh) * 2020-04-15 2023-02-03 北京辑因医疗科技有限公司 一种治疗赫勒氏综合征的方法和药物

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015367378A1 (en) 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
US11827880B2 (en) 2019-12-02 2023-11-28 Shape Therapeutics Inc. Therapeutic editing
US20230039928A1 (en) 2019-12-23 2023-02-09 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for nucleotide deamination in the treatment of Stargardt disease
JP2023529316A (ja) * 2020-05-26 2023-07-10 シェイプ セラピューティクス インコーポレイテッド ゲノム編集のための組成物及び方法
CA3248226A1 (en) * 2022-01-11 2025-07-09 Guangzhou Reforgene Medicine Co., Ltd. NUCLEOTIDE AND ITS USES
EP4479535A1 (en) 2022-02-14 2024-12-25 ProQR Therapeutics II B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
EP4555086A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Oligonucleotides for adar-mediated rna editing and use thereof
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
KR20250113455A (ko) 2022-11-24 2025-07-25 프로큐알 테라퓨틱스 Ⅱ 비.브이. 유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
JP2026510408A (ja) 2023-03-24 2026-04-02 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 神経障害の処置のためのアンチセンスオリゴヌクレオチド
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
EP4688143A1 (en) 2023-03-27 2026-02-11 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of liver disease
WO2024256620A1 (en) 2023-06-16 2024-12-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease
EP4762176A1 (en) * 2023-08-15 2026-06-24 Airna Corporation Chemically modified antisense oligonucleotides (asos) and compositions for rna editing
WO2025047679A1 (ja) * 2023-08-25 2025-03-06 学校法人福岡大学 リン酸部修飾を導入した安定型標的編集ガイドrna
EP4774393A1 (en) 2023-09-07 2026-07-15 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2025096809A1 (en) 2023-10-31 2025-05-08 Korro Bio, Inc. Oligonucleotides comprising phosphoramidate internucleotide linkages
AU2024379264A1 (en) 2023-11-16 2026-05-14 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
AU2024402199A1 (en) 2023-12-20 2026-07-16 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
WO2025155911A1 (en) 2024-01-18 2025-07-24 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of hurler syndrome
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
GB202405143D0 (en) 2024-04-11 2024-05-29 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of poly-q disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
WO2025242018A1 (zh) * 2024-05-20 2025-11-27 时夕(广州)生物科技有限公司 一种经修饰的向导agRNA
WO2026065401A1 (zh) * 2024-09-30 2026-04-02 时夕(广州)生物科技有限公司 一种用于调控SCN1A基因mRNA和蛋白表达的方法和化合物
GB202410081D0 (en) 2024-07-11 2024-08-28 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en) 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2026050243A1 (en) 2024-08-26 2026-03-05 Korro Bio, Inc. Galnac conjugated oligonucleotides for rna editing
WO2026060374A2 (en) 2024-09-16 2026-03-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2026068781A1 (en) 2024-09-30 2026-04-02 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
WO2026080897A1 (en) 2024-10-11 2026-04-16 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of chronic pain
WO2026093339A1 (en) 2024-10-29 2026-05-07 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd)
WO2026122478A1 (en) 2024-12-02 2026-06-11 Korro Bio, Inc. Extrahepatic delivery formulations and methods
WO2026136663A1 (en) 2024-12-18 2026-06-25 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease
CN119827768B (zh) * 2025-03-15 2025-06-10 广东工业大学 一种检测rna腺苷脱氨酶adar1活性的单链rna及其互补链、试剂盒与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015367378A1 (en) 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
US11274300B2 (en) 2017-01-19 2022-03-15 Proqr Therapeutics Ii B.V. Oligonucleotide complexes for use in RNA editing
EP3752611A1 (en) 2018-02-14 2020-12-23 ProQR Therapeutics II B.V. Antisense oligonucleotides for rna editing
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
AU2020210900B2 (en) * 2019-01-22 2025-04-24 Korro Bio, Inc. RNA-editing oligonucleotides and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115697420A (zh) * 2020-04-15 2023-02-03 北京辑因医疗科技有限公司 一种治疗赫勒氏综合征的方法和药物

Also Published As

Publication number Publication date
AU2020250895B2 (en) 2026-08-06
IL286395A (en) 2021-10-31
CA3132180A1 (en) 2020-10-08
JP2022527814A (ja) 2022-06-06
AU2020250895A1 (en) 2021-11-11
US20220340900A1 (en) 2022-10-27
WO2020201406A1 (en) 2020-10-08
CN113748206A (zh) 2021-12-03
EP3947679A1 (en) 2022-02-09
JP7698881B2 (ja) 2025-06-26

Similar Documents

Publication Publication Date Title
CA189498S (en) Showerbase
CA187781S (en) Banquette
GB201913756D0 (en) Contrast agent
CA189676S (en) Uroflowmeter
GB201903950D0 (en) Catalyst
CA189795S (en) Handshower
GB201806687D0 (en) Catalyst
CA189047S (en) Hammock-tent
EP4320237A4 (en) OLIGONUCLEOTIDES
GB201714330D0 (en) Oligonucleotides
GB202117092D0 (en) Oligonucleotides
CA189434S (en) Jerrycan
CA187366S (en) Hoodie
CA187077S (en) Velomobile
GB201917052D0 (en) Bioselection approach
GB201917053D0 (en) Bioselection approach
CA186582S (en) Blouson
GB201916328D0 (en) Disclosure
GB201916329D0 (en) Disclosure
GB201916327D0 (en) Disclosure
GB201918958D0 (en) Safetyfirstcam
GB201917205D0 (en) Use
GB201915787D0 (en) St
GB201915701D0 (en) St
GB201915629D0 (en) St

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)